Información del producto
Aflutinib is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Aflutinib was developed by Pfizer and is currently in phase II clinical trials for cancer treatment. This drug has been shown to be effective against cancers that overexpress EGFR, including lung cancer, pancreatic cancer, breast cancer, colorectal cancer, and head-and-neck cancers. The mechanism of action is inhibition of DNA synthesis by blocking the phosphorylation of tyrosine residues on the EGFR receptor. Aflutinib also binds to mesenchymal markers expressed at high levels in many cancers. This binding inhibits the activation of downstream signaling pathways such as RAS/RAF/MEK/ERK and PI3K/AKT pathways, leading to cell death.
Aflutinib has been shown to cause toxic epidermal necrolysis in some patients with
Propiedades químicas
Consulta técnica sobre: 3D-UZC05783 Aflutinib
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
